Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome

PurposeThe purpose of this study was to determine whether specific HOXA epigenetic signatures could differentiate glioma with distinct biological, pathological, and clinical characteristics.MethodsWe evaluated HOXA3, 7, 9, and 10 methylation in 63 glioma samples by MassARRAY and pyrosequencing.Result sWe demonstrated the direct statistical correlation between the level of methylation of all HOXA genes examined and WHO grading. Moreover, in glioblastoma patients, higher level of HOXA9 and HOXA10 methylation significantly correlated with increased survival probability (HOXA9—HR: 0.36, P = 0.007; HOXA10—HR: 0.46, P = 0.045; combined HOXA9 and 10—HR 0.28, P = 0.004).ConclusionsThis study identifies HOXA3, 7, 9, and 10 as methylation targets mainly in high-grade glioma and hypermethylation of the HOXA9 and 10 as prognostic factor in glioblastoma patients. Our data indicate that these epigenetic changes may be biomarkers of clinically different subgroups of glioma patients that could eventually benefit from personalized therapeutic strategies.

[1]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[2]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[3]  J. Estève,et al.  Cancer in the European Community and its member states. , 1990, European journal of cancer.

[4]  Nader Sanai,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma. , 2010, World neurosurgery.

[5]  Miguel Alaminos,et al.  A microarray-based DNA methylation study of glioblastoma multiforme , 2009, Epigenetics.

[6]  Taylor Jensen,et al.  Epigenetic inactivation of the HOXA gene cluster in breast cancer. , 2006, Cancer research.

[7]  H. Dudek,et al.  Neoplasms of the central nervous system of lipoid origin. , 2000, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[8]  J. McPherson,et al.  Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA. , 2007, Genome research.

[9]  J. Costello,et al.  Molecular epigenetics and genetics in neuro-oncology , 2009, Neurotherapeutics.

[10]  A. Riggs,et al.  Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay , 2007, Proceedings of the National Academy of Sciences.

[11]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[12]  G. Reifenberger,et al.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.

[13]  R. Abdel-Fattah,et al.  Differential expression of HOX genes in neoplastic and non‐neoplastic human astrocytes , 2006, The Journal of pathology.

[14]  I. Gut,et al.  Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. , 2003, BioTechniques.

[15]  Robert Brown,et al.  Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis , 2007, Clinical Cancer Research.

[16]  M. Cantile,et al.  Homeobox genes in normal and malignant cells , 2001, Journal of cellular physiology.

[17]  J. Tost,et al.  DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker. , 2009, Methods in molecular biology.

[18]  T. Spector,et al.  Epigenetic differences arise during the lifetime of monozygotic twins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Jean-Yves Delattre,et al.  Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. , 2011, Neuro-oncology.

[20]  G. Tonini,et al.  Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high‐risk, neuroblastic tumor patients , 2010, International journal of cancer.

[21]  K. Sasaki,et al.  Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization , 1998, Genes, chromosomes & cancer.

[22]  Ali S. Hadi,et al.  Finding Groups in Data: An Introduction to Chster Analysis , 1991 .

[23]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[24]  U. Lehmann,et al.  Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.

[25]  Martin Widschwendter,et al.  HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study , 2009, International journal of cancer.

[26]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[27]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Reis,et al.  MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. , 2010, Cancer research.

[29]  P. Laird.  Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[30]  E. Domany,et al.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Michael J. Terry,et al.  HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas , 2002, Oncogene.

[32]  Yuan Qi,et al.  Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak , 2010 .

[33]  John K Field,et al.  Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[35]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[36]  J. Costello,et al.  Epigenetic mechanisms in glioblastoma multiforme. , 2009, Seminars in cancer biology.

[37]  Jane Fridlyand,et al.  Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. , 2010, Cancer research.

[38]  Peter J. Rousseeuw,et al.  Finding Groups in Data: An Introduction to Cluster Analysis , 1990 .

[39]  W. Gehring,et al.  Homeotic genes and the homeobox. , 1986, Annual review of genetics.

[40]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[41]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.